Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I study of bevacizumab and sorafenib combined with low dose cyclophosphamide in patients with refractory solid tumors and leukemia.

Trial Profile

Phase I study of bevacizumab and sorafenib combined with low dose cyclophosphamide in patients with refractory solid tumors and leukemia.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Cyclophosphamide (Primary) ; Sorafenib (Primary)
  • Indications Bone cancer; Leukaemia; Lymphoma; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Apr 2020 Results (N=24), subgroup analysis of an expansion cohort assessing tolerability and drug activity patients with refractory or recurrent solid tumors, published in the European Journal of Cancer
    • 27 Aug 2019 Results assessing population pharmacokinetic modeling by using data from two studies (RELHEM and ANGIO1) published in the Clinical Cancer Research.
    • 07 Jun 2016 Results from an expansion part of this trial (n=24) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top